CalciMedica (CALC)
NASDAQ:CALC
Top Page
CalciMedica
(NASDAQ:CALC)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.59
▼(-5.48% Downside)
Action:DowngradedDate:03/19/26
The score is primarily pressured by weak financial fundamentals (no revenue, ongoing cash burn, and negative equity) and a poor technical setup (price far below longer-term moving averages with negative MACD). Valuation offers little support due to large losses and no dividend, while recent corporate events add risk via delisting warnings and the halted Phase 2 trial despite a modest runway extension.
Positive Factors
Low Leverage
Absence of debt reduces fixed obligations and bankruptcy risk, preserving financial flexibility for a clinical-stage biotech. Over the next 2–6 months this lowers cash-flow stress from interest payments and preserves optionality for financing, partnerships or targeted R&D spend.
Negative Factors
Pre-revenue with Sustained Cash Burn
Zero revenue and recurring ~-$21M operating cash burn creates persistent funding needs. Over the next several months this raises dilution and refinancing risk, constrains long-term R&D plans without new capital, and forces prioritization of programs or further cost cuts.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Absence of debt reduces fixed obligations and bankruptcy risk, preserving financial flexibility for a clinical-stage biotech. Over the next 2–6 months this lowers cash-flow stress from interest payments and preserves optionality for financing, partnerships or targeted R&D spend.
Read all positive factors
CalciMedica (CALC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.73M
Dividend YieldN/A
Average Volume (3M)71.94K
Price to Earnings (P/E)―
Beta (1Y)0.07
Revenue GrowthN/A
EPS Growth-2.46%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.68
Shares Outstanding15,743,916
10 Day Avg. Volume167,963
30 Day Avg. Volume71,939
Financial Highlights & Ratios
PEG Ratio-54.43
Price to Book (P/B)-14.90K
Price to Sales (P/S)0.00
P/FCF Ratio-4.66K
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.61K
Enterprise Value/Ebitda-0.36
Forecast
1Y Price Target
$10.00Price Target Upside1512.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
CalciMedica Business Overview & Revenue Model
Company Description
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels ...
How the Company Makes Money
null...
CalciMedica Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
28
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -46.00K | 0.00 | 0.00 | 0.00 | -519.00K |
| EBITDA | -23.12M | -24.15M | -38.02M | -7.64M | -35.30M |
| Net Income | -29.56M | -13.70M | -34.36M | -7.82M | -35.82M |
Balance Sheet | |||||
| Total Assets | 13.59M | 19.79M | 12.19M | 3.35M | 69.09M |
| Cash, Cash Equivalents and Short-Term Investments | 13.02M | 18.67M | 11.24M | 1.33M | 63.67M |
| Total Debt | 9.70M | 0.00 | 0.00 | 5.36M | 0.00 |
| Total Liabilities | 20.23M | 5.38M | 4.03M | 12.58M | 4.07M |
| Stockholders Equity | -6.64M | 14.41M | 8.16M | -9.23M | 65.02M |
Cash Flow | |||||
| Free Cash Flow | -21.21M | -21.15M | -25.81M | -11.76M | -31.99M |
| Operating Cash Flow | -21.18M | -21.15M | -25.73M | -11.76M | -31.50M |
| Investing Cash Flow | 9.55M | -4.42M | 8.88M | -4.00K | 10.75M |
| Financing Cash Flow | 15.21M | 27.97M | 20.90M | 8.48M | 695.00K |
CalciMedica Technical Analysis
Negative
0.62
Price Trends
0.64
Negative
2.75
Negative
2.83
Negative
Market Momentum
-0.10
Negative
40.55
Neutral
48.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CALC, the sentiment is Negative. The current price of 0.62 is below the 20-day moving average (MA) of 0.64, below the 50-day MA of 0.64, and below the 200-day MA of 2.83, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 40.55 is Neutral, neither overbought nor oversold. The STOCH value of 48.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CALC.
CalciMedica Risk Analysis
CalciMedica disclosed 71 risk factors in its most recent earnings report. CalciMedica reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CalciMedica Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $60.28M | -1.18 | -241.96% | ― | ― | 29.95% | |
47 Neutral | $22.17M | -2.03 | -1.04% | ― | ― | 1.18% | |
44 Neutral | $24.03M | -0.53 | -143.59% | ― | ― | -53.18% | |
43 Neutral | $27.19M | -0.40 | -197.68% | ― | ― | 78.60% | |
40 Underperform | $9.73M | -3,346.34 | -526.36% | ― | ― | -2.46% |
* Healthcare Sector Average
CALC
CalciMedica
0.63
-1.01
-61.66%
PDSB
PDS Biotechnology
1.09
0.01
0.93%
SKYE
Skye Bioscience
0.72
-0.59
-44.89%
LTRN
Lantern Pharma
2.22
-1.31
-37.11%
SNTI
Senti Biosciences
0.90
-2.38
-72.53%
CalciMedica Corporate Events
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
CalciMedica Receives Nasdaq Deficiency Notices on Listing Standards
Negative
Mar 18, 2026
On March 13, 2026, CalciMedica, Inc. received notice from Nasdaq that it was not in compliance with Listing Rule 5550(b)(2) because its market value of listed securities had been below the $35 million minimum for 30 consecutive business days, and ...
Business Operations and StrategyFinancial Disclosures
CalciMedica Ends KOURAGE Trial, Extends Cash Runway
Negative
Jan 28, 2026
On January 28, 2026, CalciMedica announced it had discontinued its Phase 2 KOURAGE clinical trial, acting on a recommendation from the study’s Independent Data Monitoring Committee, marking a setback in the advancement of that particular dru...
Business Operations and StrategyRegulatory Filings and Compliance
CalciMedica Halts Phase 2 KOURAGE Trial After Safety Review
Negative
Jan 28, 2026
On January 28, 2026, CalciMedica announced it had discontinued its Phase 2 KOURAGE clinical trial of Auxora in patients with Stage 2 or 3 acute kidney injury with associated acute hypoxemic respiratory failure, following a recommendation from the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.